US › Healthcare

Mesoblast Ltd (MESO)

US · Healthcare · Biotechnology

$14.80+2.28%

Last close · 2026-08-04

Latest quarter · ended 2025-12-31

Revenue

$25.7M

Revenue YoY

+1526.8%

Net profit

$-20.1M

Profit YoY

+16.2%

EPS

$0.00

EPS estimate

$-0.05

Net margin

-78.2%

EPS came in at 0.00 against a street estimate of -0.05 — a beat of 100.0%.

Key statistics

Market cap

$1.84B

Forward P/E

454.5

P/B

3.20

Book value

$4.46

EPS (TTM)

$-0.67

52-week high

$21.50

52-week low

$12.66

50-day MA

$14.91

200-day MA

$16.08

Beta

0.80

Analyst view

Analysts rate Mesoblast Ltd a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $35.00.

Shareholding

Insiders

5.04%

Institutions

3.00%

Largest institutional holders

Fund	Stake
BlackRock Inc	0.49%
Morgan Stanley - Brokerage Accounts	0.40%
The Goldman Sachs Group Inc	0.31%
Susquehanna International Group, LLP	0.30%
UBS Group AG	0.10%
Bank of America Corp	0.08%
Jane Street Group LLC	0.08%
Penbrook Management LLC	0.07%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Mesoblast Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.